CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Investigation Opened Following Massive Stock Crash

Capricor stock crashed after FDA revealed its lead drug failed key trial endpoints.

What the company is saying

The announcement, issued by Hagens Berman, communicates that it has launched an investigation into Capricor Therapeutics, Inc. (NASDAQ:CAPR) following a major share price collapse. The law firm frames the narrative around the FDA's disclosure that Capricor's HOPE-3 study for Deramiocel failed to meet primary and secondary efficacy endpoints, directly contradicting earlier company claims of strong, statistically significant results. The language emphasizes investor losses and the firm's experience in recovering over $2.9 billion in similar cases, encouraging affected investors to come forward. The release highlights the timeline: a December 2025 announcement of positive topline results, a subsequent 370% share price surge, a public offering of 6 million shares at $25, and the July 2026 FDA briefing that triggered a 40% to 64% share price collapse. There is no direct statement from Capricor in this release, nor any attempt to defend or contextualize the company's prior messaging. The tone is factual but negative, focused on regulatory findings and investor recourse.

What the data suggests

The numbers show a dramatic reversal in Capricor's market valuation. On December 3, 2025, Capricor shares rose $23.60, a 370% increase, after announcing positive topline results from the HOPE-3 study. The following day, the company attempted to capitalize on this surge by launching a public offering of about 6 million shares at $25 per share. On July 27, 2026, the FDA published a briefing stating the HOPE-3 trial did not meet its pre-specified primary and secondary endpoints, with no statistically significant difference between Deramiocel and placebo at 12 months. The FDA also cited at least two changes to the statistical analysis plan, including endpoint and analytical method modifications. Following this disclosure, Capricor shares fell 40% to 64%, closing at $7. No operational, cash flow, or profitability data is provided. The evidence points to a severe loss of investor confidence and a deteriorating financial trajectory, with no disclosed mitigating factors.

Analysis

The announcement is a law firm press release regarding an investigation into Capricor Therapeutics, Inc. following a dramatic share price collapse after the FDA disclosed that the HOPE-3 study failed to meet its primary and secondary endpoints. The tone is negative, reflecting the regulatory setback and subsequent financial losses. There is no promotional or exaggerated language about future prospects; the only forward-looking statement concerns potential whistleblower rewards, which is procedural rather than aspirational. The capital raise (public offering of 6 million shares at $25) is disclosed, but the benefits were not realised, as the share price collapsed soon after. No profitability, revenue, or operational metrics are disclosed, and the announcement is factual and event-driven, not promotional. The gap between narrative and evidence is minimal, as the release simply reports adverse events and the investigation, with no attempt to inflate the company's prospects.

Risk flags

• ●Regulatory risk is acute, as the FDA briefing document states the HOPE-3 study failed to meet primary and secondary efficacy endpoints, undermining the central value proposition of Deramiocel. This directly impacts the company's prospects for product approval and future revenue.
• ●Disclosure risk is high due to the FDA's identification of multiple changes to the statistical analysis plan, including endpoint definitions and analytical methods. Such protocol modifications can raise questions about data integrity and transparency, increasing the likelihood of regulatory or legal scrutiny.
• ●Financial risk is elevated following the failed trial outcome and share price collapse. The company's attempt to raise capital through a 6 million share offering at $25 per share is now in question, as the stock closed at $7 after the FDA disclosure, potentially leaving Capricor undercapitalized.
• ●Litigation risk is material, with Hagens Berman initiating an investigation into whether Capricor misled investors about trial efficacy. This could result in costly legal proceedings, settlements, or further reputational damage.

Bottom line

This announcement signals a major negative inflection point for Capricor Therapeutics, Inc. The FDA's finding that Deramiocel failed to meet key trial endpoints removes the foundation for prior bullish claims and erases the credibility of the December 2025 topline results announcement. The subsequent 40% to 64% share price collapse and the mismatch between the $25 offering price and the $7 post-disclosure close indicate severe financial and operational instability. The absence of any company response or new operational data leaves investors with no basis for optimism or clarity on future prospects. Hagens Berman's involvement underscores the seriousness of potential disclosure failures, but their track record does not guarantee investor recovery. For investors, the most important takeaway is that Capricor's lead asset faces regulatory, financial, and legal headwinds with no disclosed path to recovery. Any future investment case would require transparent disclosure of operational metrics, regulatory remediation, and credible management responses.

Announcement summary

(NASDAQ: CAPR) Capricor Therapeutics, Inc. shares plummeted roughly 40% to 64% following the U.S. Food and Drug Administration's (FDA) publication of its briefing document ahead of the advisory committee meeting for Deramiocel’s biologics license application (BLA) on July 27, 2026. On December 3, 2025, Capricor announced “Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy,” which sent the price of Capricor shares up $23.60, or 370% higher on that day. The next day, the company launched a proposed public offering of about 6 million shares priced at $25 per share. The FDA briefing document stated that the HOPE-3 study “did not meet its pre-specified primary and secondary efficacy endpoints showing no statistically significant difference between deramiocel and placebo at 12 months.” The FDA also noted “changes were made to the pre-specified [SAP], generating at least 2 additional versions,” including modifications to endpoint definitions, analytical methods, and data imputation. The price of Capricor shares closed at $7 on July 27, 2026, after the news. Hagens Berman has opened an investigation into whether Capricor misled investors about the efficacy and trial results of Deramiocel.

Disagree with this article?